Singapore markets closed

Precigen, Inc. (PGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3700+0.0500 (+2.16%)
At close: 04:00PM EDT
2.3800 +0.01 (+0.42%)
After hours: 05:46PM EDT

Precigen, Inc.

20374 Seneca Meadows Parkway
Germantown, MD 20876
United States
301 556 9900

Full-time employees456

Key executives

NameTitlePayExercisedYear born
Mr. Randal J. Kirk J.D.Exec. Chairman100kN/A1953
Dr. Helen Sabzevari MPH, Ph.D.Pres, CEO & Director1.77MN/A1962
Mr. Harry Thomasian Jr.Chief Financial Officer470.97kN/A1962
Mr. Donald P. LehrChief Legal Officer & Corp. Sec.690.76kN/A1975
Mr. Jeffrey Thomas PerezSr. VP of Intellectual Property Affairs603.54kN/A1972
Dr. Thomas D. ReedFounder & Chief Science OfficerN/AN/A1966
Mr. Rutul R. ShahVP & Head of Operations and PortfolioN/AN/AN/A
Mr. Steven HarasymVP & Head of Investor RelationsN/AN/AN/A
Marie RossiVP of CommunicationsN/AN/AN/A
Mr. Rob RussellVP & Head of HRN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Corporate governance

Precigen, Inc.’s ISS governance QualityScore as of 31 July 2022 is 7. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.